Nutex Health Inc. 8-K

What Happened

• Nutex Health Inc. (NUTX) filed an 8-K reporting results from its April 23, 2026 annual meeting. A total of 5,628,591 shares were eligible to vote, and 3,900,175 shares (≈69.29%) were voted. All seven director nominees were elected to approximately one‑year terms expiring at the 2027 annual meeting.

Key Details

• Director election vote totals (For / Withheld / Broker Non‑Votes):
  • Thomas T. Vo: 2,554,009 / 89,198 / 1,256,968
  • Warren Hosseinion: 2,512,649 / 130,558 / 1,256,968
  • Cheryl Grenas: 2,555,905 / 87,302 / 1,256,968
  • Michael L. Reed: 2,556,927 / 86,280 / 1,256,968
  • Scott J. Saunders: 2,532,892 / 110,315 / 1,256,968
  • Kelvin Spears: 2,525,003 / 118,204 / 1,256,968
  • Frank E. Jaumot: 2,623,902 / 19,305 / 1,256,968
• Advisory vote on executive compensation (say‑on‑pay): For 2,505,375 / Against 126,612 / Abstain 11,220 / Broker Non‑Votes 1,256,968 — the proposal was approved on an advisory basis.
• Ratification of independent auditor: Grant Thornton LLP was ratified for the year ending December 31, 2026 — For 3,841,817 / Against 25,441 / Abstain 32,917 (no broker non‑votes reported).

Why It Matters

• Governance: The re-election of all seven directors maintains the current board composition and continuity of leadership through the 2027 annual meeting.
• Compensation & oversight: The advisory approval of executive compensation signals shareholder support (non‑binding) for the company’s pay practices. Ratifying Grant Thornton LLP confirms the auditor for 2026, which is material for financial reporting and audit continuity.